Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Ocul Surf. 2019 Jul 3;17(4):729–736. doi: 10.1016/j.jtos.2019.07.005

Figure 4. MSCs administered via subconjunctival or intravenous injection promote normalization of corneal architecture and reduce corneal inflammation.

Figure 4.

Corneas were harvested at day 4 post-injury. (A) Corneal cross-sections were stained with H&E to visualize tissue structure and inflammatory cell infiltration. Harvested corneas were digested with collagenase IV and DNase I (2mg/ml each) to form a single cell suspension. The cells were stained with anti-CD45 fluorophore conjugated antibody and analyzed using flow cytometry. (B) Representative dot plots (left) and bar graph (right) showing frequencies of CD45+ cells in the corneas of mice treated with MSCs by different routes of administration, compared to untreated injured controls. (C) mRNA expression of the inflammatory cytokines Il-1β and Tnf-α were evaluated using real-time PCR. Data are representative of one of three independent experiments performed. Each experiment consisted of 3–4 animals/group. The values are shown as mean ± SD. *p<0.05. Scale bar: 100 μm.